Cat. No. | Product name | CAS No. |
DCC2160 |
Fomocaine
Local anaesthetic agent, blocking voltage-gated Na(+) currents in neurons |
56583-43-8 |
DCC2161 |
Formyl Lenalidomide
Impurity of Lenalidomide |
2197414-56-3 |
DCC2162 |
Fosmidomycin
Natural antibiotic, acting as an inhibitor of DOXP reductoisomerase |
66508-53-0 |
DCC2163 |
Fotagliptin
Novel dipeptidyl peptidase IV (DPP4) inhibitor |
1312954-58-7 |
DCC2164 |
Fotagliptin Benzoate
Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor |
1403496-40-1 |
DCC2165 |
Fotocaine
Novel Photochromic Ion Channel Blocker |
1612189-10-2 |
DCC2166 |
Fotyr-amp
Novel NO-donating antimicrobial peptide, exhibiting Staphylococcus aureus and Escherichia coli biofilm dispersion and eradication, and potent antibacterial activities in vitro |
|
DCC2167 |
Fpr-agonist-17b
Novel agonist of the formyl peptide receptor (FPR), protecting against myocardial ischaemia-reperfusion injury in mice |
|
DCC2168 |
Fr-139317
Selective ET(A) receptor antagonist |
142375-60-8 |
DCC2169 |
Fr171456
Natural specific inhibitor of mammalian NSDHL and yeast Erg26p, inhibiting an artificial Hepatitis C viral replicon, and showung broad antifungal activity |
168986-58-1 |
DCC2170 |
Fr181877
Nonprostanoid PGI2 agonist |
172936-99-1 |
DCC2171 |
Fr-190809
Potent and nonadrenotoxic ACAT inhibitor |
215589-63-2 |
DCC2172 |
Fr-190997
Novel Nonpeptide Bradykinin B2-Receptor Partial Agonist |
193344-25-1 |
DCC2173 |
Fr194921
Potent, selective, and orally active antagonist for central adenosine A1 receptors |
202646-80-8 |
DCC2174 |
Frf-01-116
Novel Potent and Selective Covalent Inhibitor of KRAS G12C |
|
DCC2175 |
Fropofol
Potent ligand for a protein site governed largely by van der Waals interactions, producing excitatory activity in tadpoles and mice; also antagonizing propofol-induced hypnosis |
87591-05-7 |
DCC2176 |
Fs2921
Novel N-Methyl-d-aspartate receptor (NMDAR) positive allosteric modulator (PAM) with potential antidepressant effects |
|
DCC2177 |
Fs-694
Novel highly potent and selective inhibitor (type 1.5 binding mode) of MAPK14 [IC50 = 0.2 nM (ELISA, cell free); KD = 1.5 nM (DiscoverX)] |
|
DCC2178 |
Ftbu-1
Novel Anabolic Selective Androgen Receptor Modulator (SARM) |
|
DCC2179 |
Fti-2628
Novel inhibitor of protein farnesyltransferase (FT), inhibiting the growth of P. falciparum in red blood cells and suppressing parasitemia |
655234-81-4 |
DCC2180 |
Fti-277 Tfa Salt
Farnesyltransferase inhibitor, inhibiting both H- and K-Ras oncogenic signaling |
1217447-06-7 |
DCC2181 |
Fto-04
Novel fat mass- and obesity-associated protein (FTO) inhibitor, preventing neurosphere formation in patient-derived glioblastoma stem cells (GSCs) without inhibiting the growth of healthy neural stem cell-derived neurospheres |
|
DCC2182 |
Ftsz Probe (r)-5
Novel specific high-affinity fluorescent probe for FtsZ antibacterial inhibitor |
|
DCC2183 |
Fty720-c2
FTY720 analog as novel potent stimulator of the activity of the protein phosphatase 2A (PP2A) |
249289-10-9 |
DCC2184 |
Fty720-mitoxy
FTY720 analog as novel stimulator of the activity of the protein phosphatase 2A (PP2A), targeting mitochondria |
1604816-11-6 |
DCC2185 |
Fumaropimaric Acid
Direct inhibitor of the p53 transactivation domain from binding to replication protein A |
125-66-6 |
DCC2186 |
Fumarprotocetraric Acid
Natural antimicrobial agent, showing neuroprotective, expectorant, and antioxidant activities |
489-50-9 |
DCC2187 |
Fumitremorgin C
Chemosensitizing agent, selectively reversing BCRP-mediated multidrug resistance to mitoxantrone, doxorubicin, and topotecan |
118974-02-0 |
DCC2188 |
Fur-2-oyl-leu-gly-nh2
Highly potent dopamine D2 modulator |
|
DCC2189 |
Furaltadone Hydrochloride
Anti-bacterial metabolite of Nitrofuran |
3759-92-0 |
DCC2190 |
Furaprevir
Novel potent Hepatitis C virus (HCV) NS3/4A protease inhibitor |
1435923-88-8 |
DCC2191 |
Furathiocarb
Insecticide, acting as an EC 3.1.1.7 (acetylcholinesterase) inhibitor |
65907-30-4 |
DCC2192 |
Fusarubin
Natural neuroprotective agent on glutamate-mediated HT22 cell death, controlling the amount of ubiquinone, up-regulating p21 expression in a p53-dependent manner, decreasing Akt phosphorylation and resulting in increased Fas ligand production and caspase- |
1702-77-8 |
DCC2193 |
Fw1256
Novel slow-releasing hydrogen sulfide (H2S) donor, inhibiting NF-κB activity and inducing cell apoptosis |
117089-08-4 |
DCC2194 |
Fxia-6f
Novel highly potent Factor XIa inhibitor with selectivity against most of the relevant serine proteases |
|
DCC2195 |
Fxia-in-1
Novel potent and selective inhibitor of FXIa, producing a robust and dose-dependent inhibition of both arterial thrombosis and MES |
|
DCC2196 |
fxr-in-12u
Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonist |
1393580-80-7 |
DCC2197 |
G202-0362
Novel antiviral agent against Rift Valley fever virus (RVFV) by blocking virus budding from the trans Golgi. |
868883-12-9 |
DCC2198 |
G-38963
Novel potent and highly specific MEK inhibitor (MEKi) |
1009330-74-8 |
DCC2199 |
G4-dna Ligand-3
Novel fluorescent specific ligand of human telomeric G-quadruplex DNA, binding to both G-tetrad and the lateral loop near the 5-end, reducing the telomere length and downregulating hTERC and hTERT mRNA expression in HeLa cells |
|
DCC2200 |
G514-0206
Inhibitor of NLRP3 inflammasome |
|
DCC2201 |
G6 Hydrochloride
Novel antibacterial and anti-biofilm agent against antibiotic resistant clinical isolates |
|
DCC2202 |
G6pdi-1
Novel G6PD inhibitor, revealing immune dependence on pentose phosphate pathway. depleting NADPH most strongly in lymphocytes, markedly decreasing inflammatory cytokine production in T calls, suppressing respiratory burst in neutrophils |
2457232-14-1 |
DCC2203 |
Gabaar Antagonist 1e
Novel potent competitive γ-aminobutyric acid type A receptor (GABA A R) antagonist (K i = 180 nM), targeting extrasynaptic α4βδ subtype, showing efficiently rescue inhibition of T cell proliferation |
|
DCC2204 |
gabra5-agonist-6
Potent and selective |
660423-57-4 |
DCC2205 |
Gac0001e5
Featured
GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies. |
929492-71-7 |
DCC2206 |
Gac0003a4
Featured
Novel LXR inverse agonist, functioning as LXR a degrader, significantly reducing LXR protein levels in PDAC cell lines |
927969-67-3 |
DCC2207 |
Gadoxetate Disodium
Liver-specific magnetic resonance imaging (MRI) contrast agent |
135326-22-6 |
DCC2208 |
Galidesivir Dihydrochloride
Novel viral RNA-dependent RNA polymerase (RdRP) inhibitor |
1373208-51-5 |
DCC2209 |
Galk-in-36
Novel inhibitor of galactokinase (GALK) |
|
DCC2210 |
Galunisertib Monohydrate
First-in-class transforming growth factor-β receptor type I inhibitor |
924898-09-9 |
DCC2211 |
Gamendazole
Novel male contraceptive agent, blocking spermatogenesis |
877766-45-5 |
DCC2212 |
Gamillus
Novel acid-tolerant green RSFP, exhibiting negative switching with especially high contrast in acidic conditions, and its off switching is caused by trans-to-cis isomerization of the chromophore hydroxyphenyl ring that accompanies protonation |
|
DCC2213 |
Gamma-actinorhodin
Natural antibiotic, displaying potent and selective bactericidal activity against key Gram-positive pathogens (including Staphylococcus aureus and enterococci) |
172886-23-6 |
DCC2214 |
Gamma-glu-gln
Mammalian metabolite, identified in plasma and cerebrospinal fluid from hyperammonaemic patients |
10148-81-9 |
DCC2215 |
Ganstigmine
Novel acetylcholinesterase inhibitor |
457075-21-7 |
DCC2216 |
Gas41 Inhibitor 19
Novel GAS41 YEATS inhibitor, blocking proliferation of NSCLC cells, and modulating expression of GAS41-dependent genes, demonstrating on-target inhibition of GAS41 in cancer cells |
|
DCC2217 |
Gat107
Novel allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), more active (+)-enantiomer of 4BP-TQS |
1476807-74-5 |
DCC2218 |
Gat1600
Novel potent CB1R ago-PAM |
|
DCC2219 |
Gat1601
Novel CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling |
|
DCC2220 |
Gat591
Novel CB1R allosteric agonist-positive modulator (ago-PAM), exhibiting augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55940) |
|
DCC2221 |
Gat592
Novel CB1R allosteric agonist-positive allosteric modulator (ago-PAM), exhibiting moderate ago-PAM potency and improved aqueous solubility with therapeutic reduction of intraocular pressure in murine glaucoma models |
|
DCC2222 |
Gat593
Novel CB1R allosteric agonist-positive modulator (ago-PAM), exhibiting augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55940) |
|
DCC2223 |
Gb-115
Antagonist of central cholecystokinin receptors |
678996-63-9 |
DCC2224 |
Gbs-149
Novel non-toxic and mammalian-specific LINE-1 inhibitor |
107036-52-2 |
DCC2225 |
Gc-204
Selective inhibitor of carbonic anhydrase IX (CAIX) |
28541-83-5 |
DCC2226 |
Gc-205
Selective inhibitor of carbonic anhydrase IX (CAIX) |
|
DCC2227 |
Gca-186
Highly potent non-nucleoside inhibitor of HIV-1 reverse transcriptase |
149950-61-8 |
DCC2228 |
Gcc5694a
Novel Potent and Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes |
|
DCC2229 |
Gcs Inhibitor Bz1
Novel glucosylceramide synthase (GCS) inhibitor, rescuing lysosomal deficits, α-synuclein pathology and neuron toxicity |
|
DCC2230 |
Gdc0575
Novel highly-selective oral checkpoint kinase 1 (Chk1) inhibitor |
1196541-47-3 |
DCC2231 |
Gdc-0575 Dihydrochloride
Novel potent, selective and orally bioavailable Chk1 inhibitor |
1657014-42-0 |
DCC2232 |
Gdc-0834
Novel Bruton's tyrosine kinase (BTK) inhibitor |
1133432-50-4 |
DCC2233 |
Gdc-0917
Novel SMAC mimetic and IAP antagonist |
1446182-94-0 |
DCC2235 |
Gdk-100017
Inhibitor of the Wnt/beta-catenin signaling pathway, suppressing cell proliferation and enhancing radiosensitivity in A549/Wnt2 cells. |
1140966-12-6 |
DCC2236 |
Gebr-7b
Novel Phosphodiesterase 4D (PDE4D) Inhibitor |
1349848-90-3 |
DCC2237 |
Geiparvarin
MAO inhibitor |
36413-91-9 |
DCC2238 |
Genaconazole
Novel antifungal agent |
120924-80-3 |
DCC2239 |
Geneseroline
Metabolite of ganstigmine, a novel acetylcholinesterase inhibitor |
123871-10-3 |
DCC2240 |
Geopyxin C
Natural covalent Cys151-dependent NRF2 activator |
|
DCC2241 |
Geopyxin F
Natural non-covalent NRF2 activator, activating NRF2 in A KEAP1-dependent but Cys151-independent manner, conferring greater protection than a Cys151-dependent analog, geopyxin C |
|
DCC2242 |
GFB-12811
Featured
GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC50 of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9). |
2775311-17-4 |
DCC2243 |
G-glu-glu
Endogenous dipeptide, activating N-methyl-D-aspartate receptors |
1116-22-9 |
DCC2244 |
Ghsr Inverse Agonist 29
Novel nonpeptidic inverse agonist of the Ghrelin Receptor (GHSR) |
|
DCC2245 |
Gi-129471
Metalloproteinase inhibitor, specifically blocking TNF-alpha secretion both in vitro and in vivo |
130370-59-1 |
DCC2246 |
Gi261520a
Potent EGFR/erbB2 dual inhibitor |
179248-64-7 |
DCC2247 |
Gic-1001
Novel oral anti-nociceptive agent, showing peripheral opioid agonistic activity and hydrogen sulphide-releasing capacity |
1456509-46-8 |
DCC2248 |
Gidazepam
Potent mitochondrial benzodiazepine receptors (MBRs) ligand; Prodrug for its active metabolite bromo-nordazepam |
129186-29-4 |
DCC2249 |
Gif-0854-r
Novel suppressor of endoplasmic reticulum (ER) stress and oxidative stress, preventing protein aggregate accumulation in vitro and in cultured hippocampal HT22 neuronal cells, as well as glutamate-induced oxytosis and erastin-induced ferroptosis |
|
DCC2250 |
Gif-0856-r
Novel suppressor of endoplasmic reticulum (ER) stress and oxidative stress, preventing protein aggregate accumulation in vitro and in cultured hippocampal HT22 neuronal cells, as well as glutamate-induced oxytosis and erastin-induced ferroptosis |
|
DCC2251 |
Gilteritinib Fumarate
Featured
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. |
1254053-84-3 |
DCC2252 |
Ginkgonitroside
Natural suppressor of mesenchymal stem cell (MSC) differentiation |
|
DCC2253 |
Ginnalin A
Natural Activator of the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells, Binding to the Subpockets of Keap1 Kelch Domain |
76746-56-0 |
DCC2254 |
Gk-136901
First-in-Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitor |
1062624-71-8 |
DCC2255 |
Gk-667
Novel water solubile prodrug of ICRF-193, penetrating into NVCMs, reaching intracellular concentrations sufficient to induce cytoprotective effects against ANT toxicity |
|
DCC2256 |
Gka-22
Novel Allosteric Activator of Human Glucokinase in the Absence of Glucose |
480463-02-3 |
DCC2257 |
Gka-71
Novel and potent glucokinase activator (GKA) |
863504-35-2 |
DCC2258 |
Gkm001
First-in-class liver-selective glucokinase activator for the treatment of type 2 diabetes |
|
DCC2259 |
glaziovianin A
Novel inhibitor of the cell cycle progression in M-phase; Inhibotor of endosome maturation |
943724-06-9 |
DCC2260 |
Glenvastatin
Novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor |
122254-45-9 |
DCC2261 |
Glft2-in-31
Novel Galactofuranosyltransferase 2 (GlfT2) inhibitor |
|
DCC2262 |
Glipentide
Second-generation sulfonylurea, promoting the accumulation of fructose 2,6-bisphosphate in hepatocytes |
32797-92-5 |
DCC2263 |
Glmu-in-5175178
Novel inhibitor of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). |
104926-84-3 |
DCC2264 |
Glo1-in-60
Novel potent Glyoxalase 1 (GLO1) inhibitor, demonstrating to penetrate the blood-brain barrier, elevating levels of methylglyoxal in the brain, and reducing depression-like behavior in mice |
|
DCC2265 |
Glo1-in-9
Novel inhibitor of glyoxalase 1 (Glo1), increasing the cellular methylglyoxal levels in human cells and suppressing the osteoclast formation of mouse bone marrow-derived macrophages |
|
DCC2266 |
Glp-2 (1-33) Acetate
Enteroendocrine hormone, stimulating the growth of intestinal epithelium |
223460-79-5 |
DCC2267 |
Glp-2r Modulator I
Ago-allosteric modulator of human GLP-2R |
338401-93-7 |
DCC2268 |
Glpg0259
The first-in-class, ATP-competitive inhibitor of MAPKAPK5 |
1195065-29-2 |
DCC2269 |
Gls1 Inhibitor Ll202
Novel inhibitor of glutaminase 1 (GLS1) with high binding affinity (SPR, Kd = 24 nM; ITC, Kd = 37 nM), exhibiting a similar in vivo antitumor activity as CB839 |
|
DCC2270 |
Glut4-activator-26b
Novel potent glucose transporter type 4 (GLUT4) translocation activator, showing a significant blood glucose lowering effect in the severe diabetic mice model |
|
DCC2271 |
Glut-i1
Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4) |
|
DCC2272 |
Glut-i2
Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4) |
|
DCC2273 |
Glut-i2-nh2
Glucose transporter inhibitor linker for insulin conjugate |
|
DCC2274 |
Glut-in-30
Novel glucose transporter (GLUT) inhibitor, exhibited high antitumor potency through the suppression of glucose uptake (IC 50 : 2.5 μM), while not cytotoxic to prostate and mammary epithelial cells |
|
DCC2275 |
Glycitin 6"-o-malonate
Metabolite of soy isoflavones, promoting the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover |
137705-39-6 |
DCC2276 |
Gm3 N-12
Novel GM3 derivative, showing excellent migration and invasion inhibitory effects in cells and marked antitumor activity in C57BL/6 mice, involving focal adhesion and ECM-receptor interaction signaling pathways |
|
DCC2277 |
Gma-839
Selective modulator of gamma-aminobutyric acid(A) receptors |
162882-76-0 |
DCC2278 |
Gmb-805
Novel potent BCR-Abl PROTAC, inducing degradation and demonstrating in vivo activity |
2489876-41-5 |
DCC2279 |
Gmb-905
Negative control for GMB-805 |
|
DCC2280 |
Gn39482
Novel Tubulin Polymerization Inhibitor |
|
DCC2281 |
Gne-0723
Novel GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of The N-methyl-d-aspartate receptor (NMDAR) |
1883518-31-7 |
DCC2282 |
Gne-0946
Novel potent and selective RORc inverse agonist |
1677667-24-1 |
DCC2283 |
Gne-203
Novel Met inhibitor |
949560-05-8 |
DCC2284 |
Gne-3476
Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM) |
951499-16-4 |
DCC2285 |
Gne-5729
Novel NMDAR PAM with both an improved pharmacokinetic profile and increased selectivity against AMPARs |
2026635-66-3 |
DCC2286 |
Gne-618
Novel inhibitor of nicotinamide phosphoribosyl transferase (NAMPT) |
1362151-42-5 |
DCC2287 |
Gne-6689
Negative control for GNE-2256 |
|
DCC2288 |
Gne-6901
Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM) |
1698900-69-4 |
DCC2289 |
Gne-783
Novel selective CHK1 inhibitor |
1200127-66-7 |
DCC2290 |
Gnf351
Novel potent aryl hydrocarbon receptor (AHR) antagonist with the capacity to inhibit both DRE-dependent and -independent activity |
1227634-69-6 |
DCC2292 |
Gnf-pf-3539
Novel Inhibitor of EGF-EGFR Interactions |
|
DCC2293 |
Gnf-pf-3600
Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites |
|
DCC2294 |
gnf-pf-3834
Dose dependent up-regulator of the level of E-cadherin in SW620 cells |
64651-39-4 |
DCC2295 |
Gnidimacrin
Natural highly potent HIV latency-reversing agent |
60796-70-5 |
DCC2296 |
Gnlpt-in-1
Novel inhibitor of Gram-negative lipoprotein trafficking |
1639933-79-1 |
DCC2297 |
Gnmt Inducer K-117
Novel potent GNMT inducer, inhibiting Huh7 cell growth in vitro and xenograft in vivo |
|
DCC2298 |
Go/ldha-in-7
Dual Glycolate Oxidase/Lactate Dehydrogenase A (GO/LDHA) Inhibitor for Primary Hyperoxaluria |
|
DCC2299 |
Gonadorelin Acetate
Agonist of the GnRH receptor, inducing the secretion of the gonadotropins follicle-stimulating hormone and luteinizing hormone from the pituitary gland and to increase sex hormone production by the gonads |
71447-49-9 |
DCC2300 |
Gossypolone
Natural inhibitor of Musashi family of RNA-binding proteins |
4547-72-2 |
DCC2301 |
Govadine
Antipsychotic and cognitive enhancer; Dopamine D1 and D2 receptor modulator |
60383-78-0 |
DCC2302 |
Govaniadine
Natural potent inducer of apoptosis in MCF-7 cell lines |
|
DCC2303 |
Go-y030
Curcumin analog, exhibiting potent growth suppressive activity in human colorectal carcinoma cells |
917813-62-8 |
DCC2304 |
Gpbar1-agonist-10
Novel selective non-steroidal agonist of G-protein bile acid receptor 1 (GPBAR1, also known as TGR5 or M-BAR) |
|
DCC2305 |
Gpi-15427
Potent PARP inhibitor |
805242-85-7 |
DCC2306 |
Gpr120-agonist-6a
Novel potent GPR120 agonist, exhibiting significant glucose-lowering effect and high selectivity over GPR40 |
|
DCC2307 |
Gpr52-agonist-17
Novel potent GPR52 agonist, dose-dependently suppressing methamphetamine-induced hyperlocomotion in mice |
|
DCC2308 |
Gpr52-agonist-1b
The first orally active GPR52 agonist |
|
DCC2309 |
Gpr52-in-43
Highly potent and specific GPR52 antagonist |
|
DCC2310 |
Gpr88 Agonist 53
Novel, potent, efficacious, and brain-penetrant GPR88 agonist (cAMP EC 50 = 14 nM) |
|
DCC2311 |
Gpr88-agonist-84
Novel potent GPR88 agonist (EC 50 = 59 nM) |
|
DCC2312 |
Gps488
Novel HIV replication blocker (EC 50 = 1.66 μM), being actively against a panel of HIV mutant strains displaying resistance to individual drugs used in antiretroviral therapy |
|
DCC2313 |
Gpx4-in-26a
Novel potent and selective ferroptosis inducer, inhibiting glutathione peroxidase 4 (GPX4) |
|
DCC2314 |
Gqc-05
Novel high affinity, potent, and selective stabilizer of the MYC G-quadruplex (G4)., inducing cytotoxicity with corresponding decreased MYC mRNA and altering protein binding to the NHE III1 region |
501662-77-7 |
DCC2315 |
G-quadruplex/i-motif Binder A9
Novel dual G-quadruplex/i-motif binder, binding to and stabilizing both G-quadruplex and i-motif, being effective in both oncogene replication and transcription |
|
DCC2316 |
Gr105659x
Potent TrkA kinase inhibitor |
|
DCC2317 |
Gr134056x
Negative control for GI181771X |
|
DCC2318 |
gr-205171 Dihydrochloride
Selective and brain penetrant NK1-receptor antagonist |
168266-51-1 |
DCC2319 |
Gr269666a
Novel inhibitor of the EGFr and C-erbB-2. |
|
DCC2320 |
Gr-55562 Dihydrobromide
5-HT1B/5-HT1D serotonin receptor antagonist |
172854-55-6 |
DCC2321 |
Gr-65630
5-HT3 receptor antagonist |
117186-80-8 |
DCC2322 |
Gramibactin
Bacterial siderophore with a diazeniumdiolate ligand system |
|
DCC2323 |
Granisetron
Potent 5HT3 antagonist |
109889-09-0 |
DCC2324 |
Grassypeptolide A
Novel Nrf2 modulator via a thus far uncharacterized mechanism |
1010433-25-6 |
DCC2325 |
Grayanotoxin Iii
Natural blocker of the voltage-gated sodium channels located in the cell membrane of neurons |
4678-45-9 |
DCC2326 |
Grc-17536
Novel orally available, potent and selective inhibitor of Transient Receptor Potential Ankyrin 1 (TRPA1) with IC50 value less than 10 nM |
1649479-05-9 |
DCC2327 |
Grc-6211
Novel oral specific TRPV1 antagonist, decreasing bladder overactivity and noxious bladder input in cystitis animal models |
1166398-35-1 |
DCC2328 |
Grincamycin B
Natural Potent Inhibitor for Glioblastoma Stem Cell via Targeting RHOA and PI3K/AKT |
|
DCC2329 |
Grk5-in-2
Novel potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor |
1642839-27-7 |
DCC2330 |
Grk6-in-18
Novel, potent, and selective G protein-coupled receptor kinase 6 (GRK6) inhibitor with an IC50 value of 6 nM against GRK6 and selectivity against a panel of 85 kinases |
|
DCC2331 |
Grl-117c
Novel CCR5 inhibitor, inhibiting the replication of wild-type R5-HIV-1 |
|
DCC2332 |
Grl-8234
Novel β-Secretase BACE1 Inhibitor, reversing memory impairments and rescuing age-related cognitive decline |
913071-81-5 |
DCC2333 |
Grp-156784
Novel allosteric inhibitor of respiratory syncytial virus (RSV) |
|
DCC2334 |
Gs-441524 Triphosphate (gs-443902 Sodium)
Novel potent inhibitor of feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies |
1355050-21-3 |
DCC2335 |
Gs-563253
Novel Inhibitor of Hepatitis C Viral Infectivity |
|
DCC2336 |
Gs-621763
Novel oral prodrug of GS-441524, inhibiting SARS-CoV-2, including variants of concern (VOC) in cell culture and human airway epithelium organoids |
|
DCC2337 |
Gs-8374
Potent and selective inhibitor of HIV-1 protease, effectively inhibiting protease mutants with amino acid insertions, also inhibiting major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease |
622865-01-4 |
DCC2338 |
Gsa-0902
Novel high potent and selective stabilizer of the MYC G-quadruplex (G4) |
1383470-29-8 |
DCC2339 |
gsh-mem
Glutamate receptor antagonist and radical scavenging agent |
1552275-58-7 |
DCC2340 |
Gsk002
Novel allosteric HIV-1 integrase (IN) inhibitor, disrupting formation of mature HIV particles |
|
DCC2341 |
Gsk059a
Novel potent EchA6 inhibitor |
|
DCC2342 |
Gsk1000163a
Potent inhibitor of AKT kinase |
|
DCC2343 |
Gsk-1004723
Novel dual H1 and H3 receptor antagonist with a long duration of action |
955359-72-5 |
DCC2344 |
Gsk1007102b Tfa Salt
Potent inhibitor of AKT kinase, showing activity against auxotrophic M. tuberculosis and being potentiated with meropenem |
|
DCC2345 |
Gsk1023156a
Novel inhibitor of polo-like kinase |
|
DCC2346 |
Gsk1030058a
Novel inhibitor of polo-like kinase |
660868-83-7 |
DCC2347 |
Gsk1104252a
Potent and selective GPR119 agonist |
1001397-20-1 |
DCC2348 |
Gsk1180781a
Novel selective inhibitor of MmpL3 mutation |
|
DCC2349 |
Gsk-1264
Novel allosteric inhibitor of human immunodeficiency virus (HIV) integrase, blocking viral replication and abnormal multimerization involving specific protein domains |
1392118-63-6 |
DCC2350 |
(BrMT)2
Non-peptidic snail toxin; Activator of the Kv1.1 potassium ion channel |
|
DCC2351 |
Gsk1370319a
Novel specific P2X(7) receptor antagonist |
1001389-31-6 |
DCC2352 |
Gsk1379767a
Novel dual inhibitor of BPTF and Brd4 |
1802251-02-0 |
DCC2353 |
Gsk1452496a
Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
878409-65-5 |
DCC2354 |
Gsk1452498a
Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
878447-28-0 |
DCC2355 |
Gsk1723980
Novel noncompetitive inhibitor of rTbIPMK |
1244641-64-2 |
DCC2356 |
Gsk1733953a
Featured
Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG |
930470-97-6 |
DCC2357 |
Gsk1829820a
Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
1443138-52-0 |
DCC2358 |
Gsk189254
Potent and selective H3 histamine receptor inverse agonist |
945493-87-8 |
DCC2359 |
Gsk1910364
Novel inhibitor of EPHX2 (epoxide hydrolase 2, alias soluble epoxide hydrolase or sEH), up-regulating cytoprotective genes and down-regulating proinflammatory cytokine production |
|
DCC2360 |
Gsk1997132b
Novel potent, metabolically stable and centrally penetrant PPARγ partial agonist |
1168138-37-1 |
DCC2361 |
Gsk2008607
Novel competitive inhibitor of rTbIPMK with respect to Ins(1,4,5)P3 |
1244644-50-5 |